世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ポイント・オブ・ケア(POC)/迅速診断検査市場:製品毎(血糖、感染症:肝炎・インフルエンザ・呼吸器、凝固)、プラットフォーム毎(マイクロフルイディクス、免疫測定法)、モード毎(処方、OTC)、エンドユーザ毎(病院、家庭看護) - 2024年までの世界市場予測

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Platform (Microfluidics, Immunoassays), Mode (Prescription & OTC), End-User (Hospitals, Home Care) - Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年11月US$4,950
シングルユーザライセンス
219 184

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)のポイント・オブ・ケア(POC)/迅速診断検査市場に関する調査レポートです。

“The point-of-care diagnostics market is projected to grow at a CAGR of 10.4% from 2019 to 2024.”

The global point-of-care diagnostics market is projected to reach USD 46.7 billion by 2024 from USD 28.5 billion in 2019, at a CAGR of 10.4%. Factors such as the high prevalence of infectious diseases in developing countries, increasing incidence of target conditions, and increasing inclination toward home healthcare across the globe are driving the market for point-of-care diagnostics. However, product recalls, a lack of alignment with test results obtained from laboratories, stringent & time-consuming approval policies, and a reluctance to change existing diagnostic practices are expected to restrain market growth.

“The glucose monitoring products segment is expected to command the largest share of the POC diagnostics market in 2019.”

Based on product, the point-of-care diagnostics market is segmented into glucose monitoring, infectious disease testing, cardiometabolic monitoring, coagulation monitoring, hematology testing, urinalysis testing, cholesterol testing, drugs-of-abuse testing, tumor/cancer markers, pregnancy & fertility testing, fecal occult testing, and other POC products. The glucose monitoring products segment is expected to command the largest share of the market in 2019. The increasing number of POC glucose monitoring devices, coupled with the growing prevalence of diabetes, is expected to drive the growth of the POC diagnostics market for glucose monitoring products in the coming years.

“The microfluidics segment is expected to register the highest growth rate in the POC diagnostics market, by platform, during the forecast period.”

On the basis of platform, the point-of-care diagnostics market is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. The microfluidics segment is expected to register the highest growth rate during the forecast period. Technological advancements and increasing initiatives by market players for developing novel microfluidics-based POC products are propelling the growth of the microfluidics market.
 
“The Asia Pacific market is expected to register the highest CAGR during the forecast period.”

The point-of-care diagnostics market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to register the highest growth rate during the forecast period, due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures in this region.

Breakdown of supply-side primary interviews:

- By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
- By Designation: C-level: 26%, Director-level: 30%, and Others: 44%
- By Region: North America: 34%, Europe: 26%, APAC: 23%, and the RoW: 17%

Prominent players of the point-of-care diagnostics market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio Diagnostic Systems (US), Sekisui Diagnostics (US), Nova Biomedical (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (Ireland).

Research Coverage

This report studies the point-of-care diagnostics market based on product, platform, mode of purchase, end user, and region. The report also studies factors affecting market growth, analyzes opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends. The report forecasts the revenue of the market segments with respect to the five key regions and their respective countries.

Key Benefits of Buying the Report:

From an insights perspective, this research report has focused on various levels of analysis, such as market share analysis of top players and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging segments of the point-of-care diagnostics market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help firms garner greater market shares.



目次

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.2.1 MARKETS COVERED 24
1.2.2 YEARS CONSIDERED FOR THE STUDY 24
1.3 CURRENCY 25
1.4 LIMITATIONS 25
1.5 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.1.1 SECONDARY DATA 27
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY DATA 29
2.1.2.1 Key data from primary sources 30
2.2 MARKET SIZE ESTIMATION 32
2.2.1 PRODUCT-BASED MARKET ESTIMATION 32
2.2.2 MARKET SIZE ESTIMATION: OVERALL POINT-OF-CARE DIAGNOSTICS MARKET 33
2.2.3 PRIMARY RESEARCH VALIDATION 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.4 RESEARCH LIMITATIONS & ASSUMPTIONS 35
2.4.1 LIMITATIONS 35
2.4.2 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 40
4.1 POC DIAGNOSTICS MARKET OVERVIEW 40
4.2 POC DIAGNOSTICS MARKET SHARE, BY PRODUCT 41
4.3 GEOGRAPHIC SNAPSHOT OF THE POC DIAGNOSTICS MARKET 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
5.2.1 DRIVERS 44
5.2.1.1 High prevalence of infectious diseases in developing countries 44
5.2.1.2 Increasing incidence of target conditions 44
5.2.1.3 Growing government support 45
5.2.1.4 Shortage of skilled laboratory technicians 45
5.2.1.5 Rising number of CLIA-waived POC tests 46
5.2.2 RESTRAINTS 46
5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints 46
5.2.2.2 Stringent and time-consuming regulatory policies 47
5.2.3 OPPORTUNITIES 47
5.2.3.1 Emerging markets 47
5.2.3.2 Healthcare decentralization—converting lab tests to POC tests 48
5.2.3.3 Increasing awareness through conferences and events 49
5.2.3.4 POC tests with multiplexing capabilities 49
5.2.4 CHALLENGES 50
5.2.4.1 Lack of alignment with definitive central lab methods 50
5.2.4.2 Inadequate knowledge about the use of POC devices in professional settings 50
5.2.4.3 Reluctance to change existing diagnostic practices 50
5.2.4.4 High cost of devices 51
5.2.4.5 Product recalls 51
5.2.5 EMERGING APPLICATIONS OF POINT-OF-CARE TESTING 52
5.2.5.1 Sepsis biomarkers 52
5.2.5.2 Stroke markers 53
5.2.5.3 Thyroid testing 53
5.2.5.4 DNA testing 54
5.2.5.5 Endocrine testing 54
6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 55
6.1 INTRODUCTION 56
6.2 GLUCOSE MONITORING PRODUCTS 56
6.2.1 GLUCOSE MONITORING PRODUCTS ACCOUNT FOR THE LARGEST SHARE OF THE POC DIAGNOSTICS MARKET 56
6.2.2 POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT,
BY PLATFORM 58
6.2.3 POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 58
6.2.4 POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT,
BY END USER 59
6.2.5 STRIPS 59
6.2.6 METERS 60
6.2.7 LANCETS & LANCING DEVICES 60
6.3 CARDIOMETABOLIC MONITORING PRODUCTS 61
6.3.1 POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY PLATFORM 62
6.3.2 POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 62
6.3.3 POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY END USER 62
6.3.4 CARDIAC MARKER TESTING PRODUCTS 63
6.3.4.1 Rising government initiatives for CVD research will contribute to market growth 63
6.3.5 POINT-OF-CARE CARDIAC MARKER TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 64
6.3.6 POINT-OF-CARE CARDIAC MARKER TESTING PRODUCTS MARKET SPLIT,
BY END USER 64
6.3.7 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 65
6.3.7.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment 65
6.3.8 POINT-OF-CARE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 65
6.3.9 POINT-OF-CARE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET SPLIT, BY END USER 66
6.3.10 HBA1C TESTING PRODUCTS 66
6.3.10.1 Government initiatives are promoting the regular use of HbA1c testing 66
6.3.11 POINT-OF-CARE HBA1C TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 67
6.3.12 POINT-OF-CARE HBA1C TESTING PRODUCTS MARKET SPLIT, BY END USER 68
6.4 INFECTIOUS DISEASE TESTING PRODUCTS 68
6.4.1 POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY PLATFORM 69
6.4.2 POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 70
6.4.3 POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER 70
6.4.4 INFLUENZA TESTING PRODUCTS 71
6.4.4.1 Rising influenza prevalence has driven the demand for influenza testing products 71
6.4.5 POINT-OF-CARE INFLUENZA TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 71
6.4.6 POINT-OF-CARE INFLUENZA TESTING PRODUCTS MARKET SPLIT,
BY END USER 72
6.4.7 HIV TESTING PRODUCTS 72
6.4.7.1 Rising prevalence of HIV to drive market growth 72
6.4.8 POINT-OF-CARE HIV TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 73
6.4.9 POINT-OF-CARE HIV TESTING PRODUCTS MARKET SPLIT,
BY END USER 73
6.4.10 HEPATITIS C TESTING PRODUCTS 74
6.4.10.1 Central and East Asia are among the highly affected regions with Hepatitis C 74
6.4.11 POINT-OF-CARE HEPATITIS C TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 75
6.4.12 POINT-OF-CARE HEPATITIS C TESTING PRODUCTS MARKET SPLIT,
BY END USER 75

6.4.13 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 76
6.4.13.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products 76
6.4.14 POINT-OF-CARE STD TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 76
6.4.15 POINT-OF-CARE STD TESTING PRODUCTS MARKET SPLIT, BY END USER 77
6.4.16 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 77
6.4.16.1 Rising prevalence of HAIs is the key factor driving market growth 77
6.4.17 POINT-OF-CARE HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 78
6.4.18 POINT-OF-CARE HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET SPLIT, BY END USER 78
6.4.19 RESPIRATORY INFECTION TESTING PRODUCTS 79
6.4.19.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests 79
6.4.20 POINT-OF-CARE RESPIRATORY INFECTION TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 79
6.4.21 POINT-OF-CARE RESPIRATORY INFECTION TESTING PRODUCTS MARKET SPLIT, BY END USER 80
6.4.22 TROPICAL DISEASE TESTING PRODUCTS 80
6.4.22.1 Increasing government funding for the use of POC in tropical disease testing will support market growth 80
6.4.23 POINT-OF-CARE TROPICAL DISEASE TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 81
6.4.24 POINT-OF-CARE TROPICAL DISEASE TESTING PRODUCTS MARKET SPLIT,
BY END USER 81
6.4.25 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 82
6.4.26 POINT-OF-CARE OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 83
6.4.27 POINT-OF-CARE OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER 83
6.5 COAGULATION MONITORING PRODUCTS 84
6.5.1 POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT,
BY PLATFORM 85
6.5.2 POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 85
6.5.3 POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT,
BY END USER 86
6.5.4 PT/INR TESTING PRODUCTS 86
6.5.4.1 PT/INR is one of the most commonly used coagulation monitoring methods 86
6.5.5 POINT-OF-CARE PT/INR TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 87
6.5.6 POINT-OF-CARE PT/INR TESTING PRODUCTS MARKET SPLIT, BY END USER 87
6.5.7 ACT/APTT TESTING PRODUCTS 88
6.5.7.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth 88
6.5.8 POINT-OF-CARE ACT/APTT TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 88
6.5.9 POINT-OF-CARE ACT/APTT TESTING PRODUCTS MARKET SPLIT, BY END USER 89
6.6 PREGNANCY & FERTILITY TESTING PRODUCTS 89
6.6.1 POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY PLATFORM 90
6.6.2 POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 90
6.6.3 POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY END USER 91
6.6.4 PREGNANCY TESTING PRODUCTS 92
6.6.4.1 Rising inclination toward home testing to support market growth 92
6.6.5 POINT-OF-CARE PREGNANCY TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 92
6.6.6 POINT-OF-CARE PREGNANCY TESTING PRODUCTS MARKET SPLIT,
BY END USER 92
6.6.7 FERTILITY TESTING PRODUCTS 93
6.6.7.1 Increasing awareness of fertility testing to drive market growth 93
6.6.8 POINT-OF-CARE FERTILITY TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 94
6.6.9 POINT-OF-CARE FERTILITY TESTING PRODUCTS MARKET SPLIT, BY END USER 94
6.7 TUMOR/CANCER MARKER TESTING PRODUCTS 95
6.7.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH 95
6.7.2 POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY PLATFORM 95
6.7.3 POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 96
6.7.4 POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY END USER 96
6.8 URINALYSIS TESTING PRODUCTS 97
6.8.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS IS DRIVING MARKET GROWTH 97
6.8.2 POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM 97
6.8.3 POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 98
6.8.4 POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT,
BY END USER 98
6.9 CHOLESTEROL TESTING PRODUCTS 99
6.9.1 RISING OBESITY LEVELS & CARDIOVASCULAR DISORDER INCIDENCE ARE THE KEY FACTORS SUPPORTING MARKET GROWTH 99
6.9.2 POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM 99
6.9.3 POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 100
6.9.4 POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT,
BY END USER 100
6.10 HEMATOLOGY TESTING PRODUCTS 101
6.10.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS WILL IMPEDE MARKET GROWTH 101
6.10.2 POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM 102
6.10.3 POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT,
 BY MODE OF PURCHASE 102
6.10.4 POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT,
BY END USER 103
6.11 DRUGS-OF-ABUSE TESTING PRODUCTS 104
6.11.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING 104
6.11.2 POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM 104
6.11.3 POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 105
6.11.4 POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT,
BY END USER 105
6.12 FECAL OCCULT TESTING PRODUCTS 106
6.12.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION 106
6.12.2 POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM 107
6.12.3 POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE 107
6.12.4 POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT,
BY END USER 108
6.13 OTHER POC PRODUCTS 108
6.13.1 OTHER POC PRODUCTS MARKET SPLIT, BY PLATFORM 109
6.13.2 OTHER POC PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE 109
6.13.3 OTHER POC PRODUCTS MARKET SPLIT, BY END USER 109
7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 111
7.1 INTRODUCTION 112
7.2 LATERAL FLOW ASSAYS 112
7.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING ADOPTION OF LFA ARE SUPPORTING MARKET GROWTH 112
7.3 DIPSTICKS 113
7.3.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS 113
7.4 MICROFLUIDICS 114
7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN POC DIAGNOSTICS 114
7.5 MOLECULAR DIAGNOSTICS 115
7.5.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH 115

7.6 IMMUNOASSAYS 116
7.6.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH 116
8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 118
8.1 INTRODUCTION 119
8.2 PRESCRIPTION-BASED PRODUCTS 119
8.2.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH 119
8.3 OTC PRODUCTS 120
8.3.1 RISING FOCUS ON HOME CARE IS EXPECTED TO BOOST DEMAND FOR OTC TESTING IN THE COMING YEARS 120
9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 122
9.1 INTRODUCTION 123
9.2 OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS 123
9.2.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING THE GROWTH OF THIS END-USER SEGMENT 123
9.3 HOSPITALS/CRITICAL CARE CENTERS 124
9.3.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS 124
9.4 HOME CARE SETTINGS 125
9.4.1 INCREASING INCLINATION TOWARDS HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT 125
9.5 OTHER END USERS 126
10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 127
10.1 INTRODUCTION 128
10.2 NORTH AMERICA 129
10.2.1 US 132
10.2.1.1 US dominated the North American Market in 2019 132
10.2.2 CANADA 134
10.2.2.1 Rising government initiatives to support the growth of the POC diagnostics market in Canada 134
10.3 EUROPE 136
10.3.1 GERMANY 138
10.3.1.1 Germany accounted for the largest share of the European market 138
10.3.2 FRANCE 139
10.3.2.1 Growing public-private collaborations for product development to drive market growth 139
10.3.3 UK 140
10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK 140
10.3.4 REST OF EUROPE 142

10.4 ASIA PACIFIC 144
10.4.1 JAPAN 147
10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period 147
10.4.2 CHINA 148
10.4.2.1 Rising investments by market players and the Chinese government to drive the growth of the POC diagnostics market in China 148
10.4.3 INDIA 150
10.4.3.1 High burden of chronic diseases to support market growth 150
10.4.4 REST OF ASIA PACIFIC 152
10.5 LATIN AMERICA 154
10.5.1 BRAZIL 156
10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil 156
10.5.2 MEXICO 157
10.5.2.1 Rising prevalence of diabetes and cancer to support market growth
in Mexico 157
10.5.3 REST OF LATIN AMERICA 158
10.5.4 MIDDLE EAST & AFRICA 158
10.5.4.1 Rising prevalence of cancer to support market growth in the MEA 158
11 COMPETITIVE LANDSCAPE 161
11.1 INTRODUCTION 161
11.2 GLOBAL MARKET SHARE ANALYSIS, 2018 161
11.3 COMPETITIVE SCENARIO 162
11.3.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 162
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 162
11.3.3 ACQUISITIONS 163
11.4 VENDOR DIVE OVERVIEW 163
11.5 VENDOR INCLUSION CRITERIA 164
11.6 VENDOR DIVE 164
11.6.1 VISIONARY LEADERS 164
11.6.2 INNOVATORS 164
11.6.3 DYNAMIC DIFFERENTIATORS 164
11.6.4 EMERGING COMPANIES 164
12 COMPANY PROFILES 166
(Business overview, Products and Services offered, Recent developments, MNM view)*
12.1 ABBOTT LABORATORIES 166
12.2 BECTON, DICKINSON AND COMPANY 170
12.3 CHEMBIO DIAGNOSTICS 173
12.4 DANAHER CORPORATION 177
12.5 JOHNSON & JOHNSON 180
12.6 ROCHE DIAGNOSTICS (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.) 183
12.7 SIEMENS HEALTHINEERS GROUP 187
12.8 EKF DIAGNOSTICS 191
12.9 QUIDEL 194
12.10 TRINITY BIOTECH 198
12.11 ACCUBIOTECH 200
12.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY) 203
12.13 NOVA BIOMEDICAL 205
12.14 PTS DIAGNOSTICS (A PART OF SINOCARE, INC.) 207
12.15 SEKISUI DIAGNOSTICS 209
*Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 211
13.1 DISCUSSION GUIDE 211
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 215
13.3 AVAILABLE CUSTOMIZATIONS 217
13.4 RELATED REPORTS 217
13.5 AUTHOR DETAILS 218

 

LIST OF TABLES

TABLE 1 RECENT WAIVERS FOR MARKET PRODUCTS 46
TABLE 2 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 56
TABLE 3 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION) 57
TABLE 4 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 58
TABLE 5 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 58
TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 59
TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 59
TABLE 8 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2017–2024 (USD MILLION) 60
TABLE 9 GLUCOSE MONITORING METERS MARKET, BY REGION,
2017–2024 (USD MILLION) 60
TABLE 10 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION) 61
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 62
TABLE 13 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 62
TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 62
TABLE 15 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 64
TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 64
TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 64
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 65
TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 66
TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 66
TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 67
TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 68
TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 68
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION) 69
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 69
TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 70
TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 70
TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 70
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 71
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 72
TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 72
TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 73
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 73
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 74
TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 75
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 75
TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 75
TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 76
TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 77
TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 77
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 78
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 78
TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 78
TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 79
TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 80
TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 80
TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 81
TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 81
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 82
TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 83
TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 83
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 83
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION) 84
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 85
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 85
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 86
TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 86
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 87
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 87
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 88
TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 88
TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 89
TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 89
TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 90
TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 90
TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 91
TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION) 91
TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 91
TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 92
TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 92
TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 93
TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 94
TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 94
TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 94
TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 95
TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 96
TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 96
TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 96
TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY PLATFORM, 2017–2024 (USD MILLION) 97
TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 98
TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION) 98
TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 99
TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 99
TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 100
TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 100
TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 101
TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 102
TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 102
TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 103
TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 103
TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 104
TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 105
TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 105
TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 106
TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION) 107
TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 107
TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION) 108
TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION) 108
TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY PLATFORM, 2017–2024 (USD MILLION) 109
TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 109
TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
 BY END USER, 2017–2024 (USD MILLION) 109
TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY REGION, 2017–2024 (USD MILLION) 110
TABLE 104 POC DIAGNOSTICS MARKET, BY PLATFORM, 2017–2024 (USD MILLION) 112
TABLE 105 LATERAL FLOW ASSAYS MARKET, BY REGION, 2017–2024 (USD MILLION) 113
TABLE 106 DIPSTICKS MARKET, BY REGION, 2017–2024 (USD MILLION) 114
TABLE 107 MICROFLUIDICS MARKET, BY REGION, 2017–2024 (USD MILLION) 115
TABLE 108 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 116
TABLE 109 IMMUNOASSAYS MARKET, BY REGION, 2017–2024 (USD MILLION) 117
TABLE 110 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION) 119
TABLE 111 PRESCRIPTION-BASED PRODUCTS MARKET, BY REGION,
2017–2024 (USD MILLION) 120
TABLE 112 OTC PRODUCTS MARKET, BY REGION, 2017–2024 (USD MILLION) 121
TABLE 113 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION) 123
TABLE 114 POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS, BY REGION, 2017–2024 (USD MILLION) 124
TABLE 115 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS/CRITICAL CARE CENTERS, BY REGION, 2017–2024 (USD MILLION) 125
TABLE 116 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2017–2024 (USD MILLION) 126
TABLE 117 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION) 126
TABLE 118 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 128
TABLE 119 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 130
TABLE 120 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 130
TABLE 121 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION) 131
TABLE 122 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 131
TABLE 123 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION) 131
TABLE 124 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 133
TABLE 125 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 135
TABLE 126 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 136
TABLE 127 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 136
TABLE 128 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION) 137
TABLE 129 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION) 137
TABLE 130 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION) 137
TABLE 131 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 139
TABLE 132 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 140
TABLE 133 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 142
TABLE 134 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 143
TABLE 135 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 145
TABLE 136 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 145
TABLE 137 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION) 146
TABLE 138 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION) 146
TABLE 139 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION) 146
TABLE 140 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 148
TABLE 141 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 150
TABLE 142 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 152
TABLE 143 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 153
TABLE 144 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 154
TABLE 145 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 154
TABLE 146 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION) 155
TABLE 147 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION) 155
TABLE 148 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION) 155
TABLE 149 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 156
TABLE 150 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 157
TABLE 151 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 158
TABLE 152 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 159
TABLE 153 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PLATFORM, 2017–2024 (USD MILLION) 160
TABLE 154 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION) 160
TABLE 155 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY END USER, 2017–2024 (USD MILLION) 160

 

LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY STEPS 26
FIGURE 2 RESEARCH DESIGN 27
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 31
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
FIGURE 5 DATA TRIANGULATION 34
FIGURE 6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2019 VS. 2024 (USD MILLION) 36
FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2019 VS. 2024 (USD MILLION) 37
FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY PLATFORM, 2019 VS. 2024 37
FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2019 VS. 2024 (USD MILLION) 38
FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 39
FIGURE 11 GROWING GOVERNMENT SUPPORT IS DRIVING THE ADOPTION OF POC DEVICES ACROSS THE GLOBE 40
FIGURE 12 GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE THE POC DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 41
FIGURE 13 ASIA PACIFIC MARKET TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 42
FIGURE 14 POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 43
FIGURE 15 POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION
(2019–2024) 128
FIGURE 16 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 129
FIGURE 17 APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 144
FIGURE 18 ROCHE DIAGNOSTICS HELD THE LEADING POSITION IN THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2018 161
FIGURE 19 VENDOR DIVE: EVALUATION OVERVIEW 165
FIGURE 20 ABBOTT LABORATORIES: COMPANY SNAPSHOT 166
FIGURE 21 BD: COMPANY SNAPSHOT 170
FIGURE 22 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT 173
FIGURE 23 DANAHER CORPORATION: COMPANY SNAPSHOT 177
FIGURE 24 JOHNSON & JOHNSON: COMPANY SNAPSHOT 180
FIGURE 25 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 183
FIGURE 26 SIEMENS HEALTHINEERS GROUP: COMPANY SNAPSHOT 187
FIGURE 27 EKF DIAGNOSTICS: COMPANY SNAPSHOT 191
FIGURE 28 QUIDEL: COMPANY SNAPSHOT 194
FIGURE 29 TRINITY BIOTECH: COMPANY SNAPSHOT 198
 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る